汉黄芩素对高脂血症小鼠的保护作用

摘要

Objective To explore the effects of wogonin on hyperlipidemia in mice and clarify the molecule mechanism. Methods Thirty mice were evenly divided into three group normal control group,model control group and treatment group. The normal control group was given normal diet,the model control group received high-fat diet,the treatment group received high-fat diet with wogonin (500 mg·kg-1 ). Results The mice developed hyperlipidemia 12 weeks after starting the high-fat diet. The body weight,visceral fat and fat index were increased (P<0. 05). After treatment,these indices were reduced ( P < 0. 01). Wogonin significantly reduced the total cholesterol ( TC),low density lipoprotein ( LDL),high density lipoprotein (HDL),except the triglyceride (TG). Compared to the model control group,the hepatic lipase(HL) and lipoprotein lipase(LPL) activity in the treatment group were recovered (P<0. 05),but HMG-CoA reductase activity was inhibited ( P<0. 01). Mechanistic study suggested that the lipid-lowering effect might be related to the lipid synthesis genes (SREBP-1c,FAS, PPARγ) and the lipid metabolism genes (PPARα,CPT-1). Conclusion Wogonin can prevent hyperlipidemia,which might be related to the regulation of enzyme activity and the changes of lipid synthesis and oxidative metabolism.%目的：研究汉黄芩素对饮食诱导下高脂血症小鼠模型的防治作用。方法将30只 C57小鼠随机分为正常对照组、模型对照组和药物干预组,每组10只。正常对照组给予普通饮食,模型对照组给予高脂饲料,药物干预组在高脂饲料基础上添加汉黄芩素500 mg·kg-1。观察汉黄芩素对模型小鼠血脂、脂代谢关键酶的影响,探讨其降脂机制。结果经过12周的高脂饮食,模型小鼠形成了明显的高脂血症,体质量增加,内脏脂肪增多,脂肪指数增加(P<0.05)。药物干预组较模型对照组体质量减轻(P>0.05),内脏脂肪明显减少(P<0.01),脂肪指数显著下降(P<0.05)。汉黄芩素明显降低总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL),但对三酰甘油(TG)影响不大。药物干预组较模型对照组肝脂酶(HL)与脂蛋白脂酶(LPL)活性恢复(P<0.05),羟甲基戊二酸单酰辅酶 A 还原酶活性被抑制(P<0.01)；分子生物学研究显示其降脂效果可能与脂合成基因(SREBP-1c,FAS,PPARγ)与脂质代谢基因(PPARα,CPT-1)的转录调控相关。结论汉黄芩素能够很好地治疗高脂血症,这一作用可能与调节脂酶活性和影响脂质合成与氧化基因相关。